Caring Brands, Inc. (NASDAQ:CABR) Short Interest Up 278.7% in May

Caring Brands, Inc. (NASDAQ:CABR) saw a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 20,796 shares, a growth of 278.7% from the May 14th total of 5,492 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 101,232 shares, the days-to-cover ratio is presently 0.2 days.

Caring Brands Stock Performance

CABR stock traded up $0.04 during trading on Friday, hitting $1.13. 33,841 shares of the company traded hands, compared to its average volume of 118,197. The firm has a market capitalization of $10.27 million and a price-to-earnings ratio of -1.77. Caring Brands has a 1 year low of $0.71 and a 1 year high of $5.35. The stock has a 50-day moving average of $1.11. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.66 and a quick ratio of 5.62.

Caring Brands (NASDAQ:CABR) last issued its earnings results on Tuesday, May 12th. The company reported ($0.27) earnings per share for the quarter.

Institutional Trading of Caring Brands

An institutional investor recently bought a new position in Caring Brands stock. Jane Street Group LLC bought a new position in Caring Brands, Inc. (NASDAQ:CABR) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned about 0.25% of Caring Brands at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Caring Brands in a research report on Friday, May 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Caring Brands has a consensus rating of “Sell”.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.